Back to Search
Start Over
Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
- Source :
-
The oncologist [Oncologist] 2007 Dec; Vol. 12 (12), pp. 1425-32. - Publication Year :
- 2007
-
Abstract
- Hepatocellular carcinoma (HCC) is a disease that requires multidisciplinary management. There has been no widely accepted standard for systemic therapy for this disease until recently. This article briefly discusses the management of earlier stage HCC, then focuses on newer agents with promise, particularly sorafenib, a drug that appears to be the new standard of care for advanced disease.
- Subjects :
- Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bevacizumab
Carcinoma, Hepatocellular pathology
Carcinoma, Hepatocellular therapy
Chemoembolization, Therapeutic adverse effects
Chemoembolization, Therapeutic methods
Combined Modality Therapy
Erlotinib Hydrochloride
Humans
Liver Neoplasms pathology
Niacinamide analogs & derivatives
Phenylurea Compounds
Quinazolines therapeutic use
Sorafenib
Antineoplastic Agents therapeutic use
Benzenesulfonates therapeutic use
Carcinoma, Hepatocellular drug therapy
Liver Neoplasms drug therapy
Protein Kinase Inhibitors therapeutic use
Pyridines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1083-7159
- Volume :
- 12
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- The oncologist
- Publication Type :
- Academic Journal
- Accession number :
- 18165619
- Full Text :
- https://doi.org/10.1634/theoncologist.12-12-1425